ECoG timescales decrease during spatial attention. حسب Isabel Raposo (21615517)

"…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …"

Expression of lipid biosynthetic genes is decreased with polyamine depletion. حسب Yazmin E. Cruz-Pulido (20285238)

الموضوعات:

In the first 15 days of pod fill high temperature over 30∘C decreased marketable yield for both seasons. حسب Miranda Y. Mortlock (20855564)

"…<p>In the first 15 days of pod fill high temperature over 30∘C decreased marketable yield for both seasons.</p>…"

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. حسب Peiqi Yin (6533747)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. حسب Ryan J. Treves (13527735)

Data from: Colony losses of stingless bees increase in agricultural areas, but decrease in forested areas حسب Malena Sibaja Leyton (18400983)

"…Moreover, annual colony losses also decreased with higher abundance of surrounding forested area. …"

ANN architecture. حسب Abdelfattah Dani (22226715)

الموضوعات:

Ether Cleavage Decreases the Ion Exchange Capacity of Anion Exchange Membranes حسب Shakkira Erimban (6882539)

الموضوعات:

Ether Cleavage Decreases the Ion Exchange Capacity of Anion Exchange Membranes حسب Shakkira Erimban (6882539)

الموضوعات:

BST2 overexpression decreased RSV multiplication. حسب Katherine Marougka (13015146)

The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. حسب Peiqi Yin (6533747)

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

ANN architecture and configuration. حسب Abdelfattah Dani (22226715)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات: